Epigenomics AG / Total Voting Rights Announcement 24.01.2022 / 11:39 Total Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of total number of voting rights1. Details of issuer Epigenomics AG Geneststraße 5 10829 Berlin Germany 2. Type of […]
Author: mark
24. January 2022
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Read more
24. January 2022
Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon ‘Next-Gen’ Colorectal Cancer Screening Test
DGAP-News: Epigenomics AG / Key word(s): Personnel24.01.2022 / 07:00 The issuer is solely responsible for the content of this announcement. Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon “Next-Gen” Colorectal Cancer Screening Test Greg Hamilton retained as CEO through 2025 Appointment underscores Epigenomics’ commitment to the […]
14. December 2021
Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer
DGAP-News: Epigenomics AG / Key word(s): Personnel14.12.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer Jens Ravens is an internationally experienced leader with in-depth experience in Controlling, Finance, M&A, IT, Legal, and Human Resources New Chief Financial Officer […]
18. November 2021
Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer
DGAP-News: Epigenomics AG / Key word(s): Personnel18.11.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer Dr. Andrew Lukowiak is a proven senior executive with deep technology and development expertise Appointment underscores Epigenomics’ commitment to the […]
10. November 2021
Epigenomics AG publishes financial results for the first nine months 2021
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results10.11.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG publishes financial results for the first nine months 2021 Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today […]
08. October 2021
Dokument gem. Art. 1 Abs. 5 lit. H) Verordnung (EU) 2017/1129
Betreffend bis zu 101.067 auf den Namen lautende Stückaktien mit Gewinnanteilsberechtigung aus bedingtem Kapital Gemäß Beschluss der Hauptversammlung der Epigenomics AG vom 30. Mai 2017 sind der Vorstand und der Aufsichtsrat der Epigenomics AG ermächtigt, bis zum Ablauf des 31. Mai 2019 Aktienoptionen an Mitglieder des Vorstands und Beschäftigte der Gesellschaft sowie an Mitglieder der […]